AMAAD Institute

AMAAD Institute is an addiction-treatment facility located in Los Angeles, CA. The facility's programming is outpatient (Outpatient, Dual Dx), not residential. What follows is an orientation — not a review — to the practical questions worth asking before admission.

Care levels at AMAAD Institute

The care-level question matters because what a facility offers is what it can realistically treat well. AMAAD Institute is an outpatient-focused program (Outpatient, Dual Dx) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Before admission, an independent clinical assessment (from a primary-care doctor, licensed substance-use counselor, or addiction-medicine physician) can confirm whether AMAAD Institute's offerings match the clinical need.

Insurance and payment

On insurance specifically: Payment and insurance specifics for AMAAD Institute are not fully documented in the SAMHSA registry — a direct admissions conversation is the reliable way to confirm what forms of payment are accepted and at what network-contract level. Before admission, ask the facility's utilization-review team for a written Verification of Benefits — not verbal assurance, which is where most post-treatment financial surprises come from. Also ask for specific plan-level confirmation, not carrier-level (e.g., "your Aetna PPO plan" not just "Aetna").

Specialty programming

The facility's documented specialty programming includes: Young adults, Seniors or older adults, Clients with HIV or AIDS. Specialty programming varies substantially by facility — some facilities offer "dual diagnosis" as a marketing category but not a clinical differentiator. Ask for the specific clinical-team credentials and the actual hours of specialty-specific content per week.

Before you call

Three questions to put to AMAAD Institute before admission: the specific ASAM level the facility is billing; the written Verification of Benefits for your specific plan product; the MAT policy (continuation of buprenorphine or methadone during residential, specifically). If the clinical situation involves opioid use disorder, confirm explicitly whether AMAAD Institute offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care. Getting answers in writing protects against the downstream surprises.